Servier
Pharma

Servier rounds out rare cancer offerings with $2.5B Day One buy

Servier has unveiled a deal to acquire commercial-stage Day One Biopharmaceuticals and its med Ojemda for $21.50 per share in cash.
Fraiser Kansteiner Mar 6, 2026 10:14am
Prasad
Favicon Fierce Biotech

CBER Director Vinay Prasad to depart FDA—again

Mar 6, 2026 5:30pm
Operating a New Standard for Life-Saving Pharmaceutical Logistics

Operating a New Standard for Life-Saving Pharmaceutical Logistics

Brought to you by Frontier Scientific Solutions
hand over keys buy house gift takeover acquisition

Lonza shakes off capsule business in $3B deal with Lone Star

Mar 6, 2026 4:00pm
US Sen Ron Wyden D-OR speaks to press in the US Capitol on February 03 2025 in Washington DC

7 Democrats press pharmas for details on Trump MFN agreements

Mar 6, 2026 2:52pm
Board room C-suite meeting contract

Sanofi sells generics unit to Brazil's EMS

Mar 6, 2026 2:00pm
More News

Super Bowl, Olympics defined TV drug ad spending in February

Mar 6, 2026 12:39pm

Taiwan unveils $755M multi-year drug supply resilience program

Mar 6, 2026 11:35am

China signs off on Pfizer, Sciwind's GLP-1 weight loss drug

Mar 6, 2026 11:22am
Fierce Biotech

FDA to end 9-month adcomm hiatus with review of AZ's cancer drugs

Mar 6, 2026 11:16am